(97) the efficacy and safety of tandem CD19/20 CAR-T cells were demonstrated in 11 patients with r/r NHL; the ORR and CR rates were 90% and 70%, respectively, while the median duration of response for the 9 responders was 11.83 months (97). The gene discussed is CD19; the disease is non-Hodgkin lymphoma.